Probiogen AG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Probiogen AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013197
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Probiogen AG (Probiogen), a subsidiary of Minapharm Pharmaceuticals & Chemical Industries is a contract development and manufacturing organization that offers cell line engineering, process development and GMP manufacturing of biopharmaceuticals. The organization’s services comprise therapeutic proteins/antibodies, viral vaccines, biosimilar and biobetter development. It offers contract cell line development, contract process development, contract manufacturing of GMP and non-GMP, protein analytics, and cell-based assays. It develops various technologies for optimized biopharmaceutical manufacturing and analysis. The organization also develops virusproduction system, adcc enhancement, yield enhancement, innovative bioassays and other technologies. Probiogen is headquartered in Berlin, Germany.

Probiogen AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Probiogen AG, Medical Devices Deals, 2011 to YTD 2017 9
Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Probiogen AG, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ProBioGen Enters into Co-Development Agreement with PT Bio Farma 11
ProBioGen Enters into Agreement with Zymeworks 12
Licensing Agreements 13
Chiome Bioscience Enters into Licensing Agreement with ProBioGen 13
ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 14
ProBioGen Enters into Licensing Agreement with Merus 15
ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 16
ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 17
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 18
ProBioGen Expands Licensing Agreement With Emergent BioSolutions For AGE1.CR Cell Line 19
Ceva Sante Animale Enters Into Licensing Agreement With ProBioGen For AGE1.CR Avian Cell Line 20
ProBioGen Enters Into Licensing Agreement With INHIBRX For GlymaxX ADCC Technology 21
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 22
Probiogen AG – Key Competitors 23
Probiogen AG – Key Employees 24
Probiogen AG – Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Probiogen AG, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Probiogen AG, Deals By Therapy Area, 2011 to YTD 2017 8
Probiogen AG, Medical Devices Deals, 2011 to YTD 2017 9
Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ProBioGen Enters into Co-Development Agreement with PT Bio Farma 11
ProBioGen Enters into Agreement with Zymeworks 12
Chiome Bioscience Enters into Licensing Agreement with ProBioGen 13
ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 14
ProBioGen Enters into Licensing Agreement with Merus 15
ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 16
ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 17
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 18
ProBioGen Expands Licensing Agreement With Emergent BioSolutions For AGE1.CR Cell Line 19
Ceva Sante Animale Enters Into Licensing Agreement With ProBioGen For AGE1.CR Avian Cell Line 20
ProBioGen Enters Into Licensing Agreement With INHIBRX For GlymaxX ADCC Technology 21
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 22
Probiogen AG, Key Competitors 23
Probiogen AG, Key Employees 24

★海外企業調査レポート[Probiogen AG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Selecta Biosciences Inc:企業のM&A・事業提携・投資動向
    Selecta Biosciences Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Selecta Biosciences Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Tenet Healthcare Corporation:企業の戦略・SWOT・財務分析
    Tenet Healthcare Corporation - Strategy, SWOT and Corporate Finance Report Summary Tenet Healthcare Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Uniper SE (UN01):企業の財務・戦略的SWOT分析
    Uniper SE (UN01) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Royal DSM NV (DSM):企業の財務・戦略的SWOT分析
    Royal DSM NV (DSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Turkiye IS Bankasi A.S.:戦略・SWOT・企業財務分析
    Turkiye IS Bankasi A.S. - Strategy, SWOT and Corporate Finance Report Summary Turkiye IS Bankasi A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Vibra Healthcare LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Vibra Healthcare LLC (Vibra) is a healthcare service provider that provides short-term rehabilitation, long-term care, skilled nursing and respite care services. The organization develops and acquires medical rehabilitation hospitals and long term acute care hospitals. It offers services suc …
  • RPM International Inc:企業の戦略・SWOT・財務情報
    RPM International Inc - Strategy, SWOT and Corporate Finance Report Summary RPM International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Photocure ASA (PHO):企業の財務・戦略的SWOT分析
    Photocure ASA (PHO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • UniQure NV (QURE):企業の財務・戦略的SWOT分析
    UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Promimic AB-医療機器分野:企業M&A・提携分析
    Summary Promimic AB (Promimic) is a biomaterial company that develops and markets implant surface modifications and synthetic bones. The company’s products comprise metals, ceramics, polymers, porous materials and pyrocarbon. Its HA-nano surface is a coating based on nanocrystalline hydroxyapatite p …
  • NovoCure Ltd (NVCR)-医療機器分野:企業M&A・提携分析
    Summary NovoCure Ltd (NovoCure) is an drug company that concentrates on the development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in various types of cancer indications such as ovarian cancer, malignant melanoma, hepatocellul …
  • ORBCOMM Inc (ORBC):企業の財務・戦略的SWOT分析
    ORBCOMM Inc (ORBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Cenovus Energy Inc.:企業の戦略・SWOT・財務情報
    Cenovus Energy Inc. - Strategy, SWOT and Corporate Finance Report Summary Cenovus Energy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Newpark Resources, Inc. (NR)-石油・ガス分野:企業M&A・提携分析
    Summary Newpark Resources, Inc. (Newpark) offers fluid systems and services to oil and gas industry. The company offers drilling fluid products, solutions and services supporting directional, horizontal and deep water drilling projects. It grinds barite, which is used as a raw material in drilling f …
  • Daidalos Solutions BV:企業の製品パイプライン分析2018
    Summary Daidalos Solutions BV (Daidalos Solutions) is a medical device company. The company offers products such as sutureless biological heart valve prostheses, sutureless mechanical heart valve prostheses, sutureless heart valve repair rings, sutureless working channels and ports, sutureless closi …
  • Sun BioPharma Inc (SNBP):企業の財務・戦略的SWOT分析
    Summary Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti- …
  • Jiangsu Jiuding New Material Co Ltd (002201):企業の財務・戦略的SWOT分析
    Jiangsu Jiuding New Material Co Ltd (002201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company that discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of …
  • Pharnext SA (ALPHA):企業の財務・戦略的SWOT分析
    Summary Pharnext SA (Pharnext), formerly Pharnext SAS is a biopharmaceutical company that develops novel therapies for severe neurodegenerative diseases. The company offers pleotherapy, a proprietary research and development platform based on network pharmacology that uses wide genomic data to ident …
  • Noble Energy, Inc.:戦略・SWOT・企業財務分析
    Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Noble Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆